Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Cornely, Oliver A.
  • dc.contributor.author Cisneros, José M.
  • dc.contributor.author Torre-Cisneros, Julian
  • dc.contributor.author Rodríguez-Hernández, María Jesús
  • dc.contributor.author Tallón-Aguilar, Luis
  • dc.contributor.author Calbo, Esther
  • dc.contributor.author Horcajada Gallego, Juan Pablo
  • dc.contributor.author Queckenberg, Christian
  • dc.contributor.author Zettelmeyer, Ulrike
  • dc.contributor.author Arenz, Dorothee
  • dc.contributor.author Rosso-Fernández, Clara M.
  • dc.contributor.author Jiménez-Jorge, Silvia
  • dc.contributor.author Turner, Guy
  • dc.contributor.author Raber, Susan
  • dc.contributor.author O'Brien, Seamus
  • dc.contributor.author Luckey, Alison
  • dc.contributor.author COMBACTE-CARE consortium/REJUVENATE Study Group
  • dc.date.accessioned 2020-06-09T06:47:52Z
  • dc.date.available 2020-06-09T06:47:52Z
  • dc.date.issued 2020
  • dc.description.abstract Objectives: To investigate pharmacokinetics (PK) and safety (primary objectives) and efficacy (secondary objective) of the investigational monobactam/β-lactamase inhibitor combination aztreonam/avibactam in patients with complicated intra-abdominal infection (cIAI). Methods: This Phase 2a open-label, multicentre study (NCT02655419; EudraCT 2015-002726-39) enrolled adults with cIAI into sequential cohorts for 5-14 days treatment. Cohort 1 patients received an aztreonam/avibactam loading dose of 500/137 mg (30 min infusion), followed by maintenance doses of 1500/410 mg (3 h infusions) q6h; Cohort 2 received 500/167 mg (30 min infusion), followed by 1500/500 mg (3 h infusions) q6h. Cohort 3 was an extension of exposure at the higher dose regimen. Doses were adjusted for creatinine clearance of 31-50 mL/min (Cohorts 2 + 3). All patients received IV metronidazole 500 mg q8h. PK, safety and efficacy were assessed. Results: Thirty-four patients (Cohort 1, n = 16; Cohorts 2 + 3, n = 18) comprised the modified ITT (MITT) population. Mean exposures of aztreonam and avibactam in Cohorts 2 + 3 were consistent with those predicted to achieve joint PK/pharmacodynamic target attainment in >90% patients. Adverse events (AEs) were similar between cohorts. The most common AEs were hepatic enzyme increases [n = 9 (26.5%)] and diarrhoea [n = 5 (14.7%)]. Clinical cure rates at the test-of-cure visit overall were 20/34 (58.8%) (MITT) and 14/23 (60.9%) (microbiological-MITT population). Conclusions: Observed AEs were consistent with the known safety profile of aztreonam monotherapy, with no new safety concerns identified. These data support selection of the aztreonam/avibactam 500/167 mg (30 min infusion) loading dose and 1500/500 mg (3 h infusions) maintenance dose q6h regimen, in patients with creatinine clearance >50 mL/min, for the Phase 3 development programme.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Cornely OA, Cisneros JM, Torre-Cisneros J, Rodríguez-Hernández MJ, Tallón-Aguilar L, Calbo E, et al. Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. J Antimicrob Chemother. 2020 Mar 1; 75(3):618-27. DOI: 10.1093/jac/dkz497
  • dc.identifier.doi http://dx.doi.org/10.1093/jac/dkz497
  • dc.identifier.issn 0305-7453
  • dc.identifier.uri http://hdl.handle.net/10230/44937
  • dc.language.iso eng
  • dc.publisher Oxford University Press
  • dc.rights Copyright © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
  • dc.subject.other Abdomen -- Malalties
  • dc.subject.other Abdomen -- Infeccions -- Tractament
  • dc.title Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)